Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.5900
-0.0120 (-1.99%)
At close: Jun 16, 2025, 4:00 PM
0.5871
-0.0029 (-0.49%)
After-hours: Jun 16, 2025, 5:16 PM EDT

Cue Biopharma Stock Forecast

CUE's stock price has decreased by -56.62% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts that cover Cue Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $3, which forecasts a 408.47% increase in the stock price over the next year. The lowest target is $2 and the highest is $4.

Price Target: $3 (+408.47%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $2.00 $3.00 $3.00 $4.00
Change +238.98% +408.47% +408.47% +577.97%
* Price targets were last updated on Apr 2, 2025.

Analyst Ratings

The average analyst rating for Cue Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25May '25Jun '25
Strong Buy 222111
Buy 333332
Hold 000000
Sell 000000
Strong Sell 000000
Total 555443

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Citizens Capital Markets
Citizens Capital Markets
Buy
Reiterates
$2
Buy Reiterates $2 +238.98% Apr 2, 2025
Stifel
Stifel
Strong Buy
Maintains
$8$4
Strong Buy Maintains $8$4 +577.97% Aug 20, 2024
JMP Securities
JMP Securities
Buy
Maintains
$15$2
Buy Maintains $15$2 +238.98% Jul 26, 2024
Piper Sandler
Piper Sandler
Buy
Maintains
$8$3
Buy Maintains $8$3 +408.47% Jul 26, 2024
Stifel
Stifel
Strong Buy
Maintains
$8
Strong Buy Maintains $8 +1,255.93% Apr 9, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
8.16M
from 9.29M
Decreased by -12.18%
Revenue Next Year
10.10M
from 8.16M
Increased by 23.84%
EPS This Year
-0.58
from -0.72
EPS Next Year
-0.52
from -0.58
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
3.15M14.94M1.25M5.49M9.29M8.16M10.10M20.71M
Revenue Growth
-8.79%373.68%-91.67%340.96%69.16%-12.18%23.84%105.00%
EPS
-1.56-1.41-1.49-1.11-0.72-0.58-0.52-0.50
EPS Growth
--------
Forward PE
--------
No. Analysts
-----554
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 10.2M 10.5M 21.5M
Avg 8.2M 10.1M 20.7M
Low 6.3M 9.8M 20.1M

Revenue Growth

Revenue Growth 20252026202720282029
High
10.3%
28.7%
113.1%
Avg
-12.2%
23.8%
105.0%
Low
-32.5%
20.2%
98.9%

EPS Forecast

EPS 20252026202720282029
High -0.56 -0.33 -0.51
Avg -0.58 -0.52 -0.50
Low -0.62 -0.65 -0.49

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.